News
AGN
0.0000
0.00%
0.00
Biogen: LAQEMBI's $10 Billion Potential
Biogen's latest alzheimer's drug, aduhelm, faced challenges after fda approval. The company's latest drug, a new type of alzheimer's treatment, has raised concerns. Biogen has a $10 billion potential, according to main street investor's analysis of the stock.
Seeking Alpha · 11/29/2023 20:00
More
Webull provides a variety of real-time AGN stock news. You can receive the latest news about Allergan through multiple platforms. This information may help you make smarter investment decisions.
About AGN
Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.